Evoke Wealth’s Co-Diagnostics CODX Stock Holding History

Evoke Wealth’s Portfolio CODX Stock Details CODX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-6	Closed	-$2K	–	1172
2021 Q1	$2K	Buy	+6	New	+$2.4K	﹤0.01%	1014

Other funds holding CODX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PPA

Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ARC

Advisor Resource Council Dallas, Texas $355M AUM 30.05% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Evoke Wealth's CODX Position: Q2 2021 in Review

Evoke Wealth sold out of Co-Diagnostics (CODX) in Q2 2021, closing a stake of 6 shares — an estimated $2K sold.

Evoke Wealth first reported a position in CODX in Q1 2021 and held it in 1 quarter. The position peaked at $2K in Q1 2021. 88 funds tracked by Wall St. Rank hold CODX as of Q2 2021.

Evoke Wealth reported no remaining Co-Diagnostics position as of Q2 2021 after selling out during the quarter.
Evoke Wealth sold 6 Co-Diagnostics shares in Q2 2021, an estimated $2K.
Evoke Wealth first reported a position in Co-Diagnostics in Q1 2021 and held it in 1 quarter.
Evoke Wealth's Co-Diagnostics position peaked at $2K in Q1 2021.
88 funds tracked by Wall St. Rank held Co-Diagnostics as of Q2 2021.

Based on Evoke Wealth's 13F filing for Q2 2021, filed 5 Aug 2021.